EASL大咖专访｜Tarik Asselah教授：荟萃一堂，通力协作，共创肝病诊治新未来

第58届欧洲肝脏研究学会年会（EASL 2023）暨2023年EASL大会（EASL Congress 2023）于6月21日-24日在奥地利维也纳盛大召开，这是全球肝病领域极具影响力的国际会议，汇聚前沿学术动态、新近研究成果与重磅专题报告。值此会议之际，医脉通特邀法国巴黎大学、Beaujon医院Tarik Asselah教授分享肝病领域学术进展和参会感受。

医脉通：您刚才关于HDV患者管理和治疗方面的演讲非常精彩。请问您能否谈谈关于HDV感染管理和治疗的环境和未来趋势。

Tarik Asselah教授：非常感谢邀请。这次EASL会议规模庞大，有数千名来自世界各地的参会者。在会议上，我们发布了欧洲HDV患者管理指南，旨在帮助临床医生更好地管理HDV患者。这是非常令人兴奋和有意义的一次会议。

Pro. Tarik Asselah: So this is the easel meeting. It's a very large meeting, several thousand of people coming for worldwide. And it was a very interesting meeting on liver disease. And so for your question about Delta, we release during this meeting the European guidance for taking care of patients with delta. So it's very interesting because this guidance is to help clinician to take care of these questions.

医脉通：EASL大会是肝病学领域的年度国际盛会。能否分享一下您参加今年EASL大会的感受？

Tarik Asselah教授：是的，这是一个非常重要的会议，因为它涵盖了肝病领域的各个方面。我很高兴参加今年的EASL大会。在我所关注的乙型肝炎领域，药物研发出现了许多新进展。目前已发现一些有效且耐受性良好的治疗方案，但通常需要长期治疗，并可能产生副作用。因此，仍然需要不断改进治疗方案以实现治愈。此外，虽然HDV感染比HBV感染更为罕见，但我们仍然需要关注它。我很期待了解有关HDV感染的最新研究和治疗进展。我参与制定的新版HDV指南建议对所有乙型肝炎患者进行HDV筛查，并确保他们获得适当的治疗。Bulevirtide于2020年附条件获批，这为我们治疗患者提供了新的选择。此外，还有其他干扰素和许多药物正处于研发中，例如Lonafarnib。我相信这些研究和创新对于改善患者的疾病管理和治疗非常重要。我期待着在EASL大会上与其他专家和研究人员交流并了解他们的最新研究成果和见解。

Pro. Tarik Asselah: Yes, this is a very important conference as it covers various aspects of liver disease. I am excited to attend this year's EASL meeting. In the field of hepatitis B, which is my focus, there are many new developments in drug research aiming to cure this disease. We now have some effective and well-tolerated treatment options, but they often require long-term therapy and can have adverse effects. Therefore, there is still a need for continuous improvement and achieving a cure. Additionally, although the Delta virus is rarer than hepatitis B, we still need to pay attention to it. I am looking forward to learning about the latest research and treatment advances related to the Delta virus. In the Delta guidelines that I am involved in, we recommend screening all patients with hepatitis B for Delta and ensuring they receive appropriate treatment. I am pleased to see that the conditional approval of Bulevirtide was granted in 2020, providing us with a new option for treating patients. Furthermore, there are other interferons and many drugs under development, such as Lonafarnib. I believe these research and innovations are crucial for improving disease management and treatment for patients. I am excited to engage with other experts and researchers at the EASL meeting and learn about their latest findings and insights.

医脉通：最近中国医生对于国际会议越来越关注，目的是为了提高国际交流和创新。您作为肝病领域的顶级专家，拥有大量学术成就，请问您是否可以分享一下您对于国际交流合作和学术创新价值的见解和经验，给中国医生一些建议。

Tarik Asselah教授：在学术研究中，与各位学者合作非常重要。没有边界，没有国界。中国是一个非常大的国家，有很多优秀的研究团队，我们互相学习。我们也从中国学到了很多重要的东西，因为中国拥有技术、经验和大量的患者，包括在乙型肝炎和丁型肝炎领域。因此我们也很高兴中国学者参加国际会议。我认为中国和欧洲的合作非常重要。

Pro. Tarik Asselah: In academic research, it is very important to cooperate with everyone. No borders, no borders. China is a very large country with a rich culture and many key opinion leaders. There are many excellent research teams in China, and we learn from each other. We have also learned a lot of important things from China because China has the technology, experience and a large number of patients, including hepatitis B and hepatitis D. So we are also glad that Chinese doctors and leaders have also attended these meetings. Of course, many of them are very powerful and expert. I think cooperation with China and Europe is very important. We are very happy. I know that many of our colleagues from China are very strong and smart.

Tarik Asselah, MD

• Full Professor of Medicine and Hepatology at Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, France.

• He is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation).

• He is an MD and holds a PhD in virology.

• His research focuses on chronic liver diseases, translational medicine, and the treatment of HBV, HCV, and HDV infections using new direct-acting antivirals. Dr. Asselah has been involved as a coordinator/principal investigator in several clinical trials and has coordinated major international trials on HCV Genotype 4 infection, HBV, and HDV.

• He has published over 250 articles in renowned journals and has received awards for his scientific work in the field of hepatology.